Podcast appearances and mentions of Johnson Johnson

Johnson & Johnson reported its latest earnings and announced a separation of its orthopedics business into a standalone company. CEO Joaquin Duato discusses the company's next era, new warning labels for its multiple myeloma treatment Carvykti, and the future of J&J's consumer. Then, it's publication day for Andrew Ross Sorkin's new book 1929, which details the stock market crash that reshaped American capitalism. Plus, China sanctions a South Korean shipbuilder accused of aiding the U.S., and President Trump weighs in on a two-state solution and rebuilding Gaza. Joaquin Duato - 10:25 In this episode:Joe Kernen, @JoeSquawk Becky Quick, @BeckyQuickAndrew Ross Sorkin, @andrewrsorkinCameron Costa, @CameronCostaNY Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Carl Quintanilla, Jim Cramer and David Faber discussed stock markets down sharply after Monday's rebound rally — as trade tensions between the U.S. and China re-escalate. The anchors also delved into big banks kicking off earnings season, including quarterly results from JPMorgan Chase, Wells Fargo, Goldman Sachs and Citigroup. BlackRock Chairman & CEO Larry Fink joined the show at Post 9 to talk about earnings as well as the investment landscape both globally and in the U.S. Also in focus: The latest on OpenAI, hear what Oracle's new CEOs and Broadcom CEO Hock Tan had to say about AI, Johnson & Johnson's upbeat quarterly results and outlook. Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Host: Susanna Price Guest: Rudolf de Boer Want to watch that extended interview on AI in echocardiography? Go to: https://esc365.escardio.org/event/2175?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Rudolf de Boer has declared to have potential conflicts of interest to report: the institution of Rudolf de Boer has received research grants and/or fees from Alnylam, AstraZeneca, Abbott, Bristol-Myers Squibb, NovoNordisk, and Roche; Rudolf de Boer has had speaker engagements with and/or received fees from and/or served on an advisory board for Abbott, AstraZeneca, Bristol Myers Squibb, NovoNordisk, Roche, and Zoll; Rudolf de Boer received travel support from Abbott and NovoNordisk. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Visceral adiposity: paradigm shift in HFpEF management Artificial Intelligence in echocardiography Milestones: ISIS-2 Host: Susanna Price Guests: Carlos Aguiar, Milton Packer, Rudolf de Boer Want to watch the episode? Go to: https://esc365.escardio.org/event/2175 Want to watch the extended interview on AI in echocardiography? Go to: https://esc365.escardio.org/event/2175?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Rudolf de Boer has declared to have potential conflicts of interest to report: the institution of Rudolf de Boer has received research grants and/or fees from Alnylam, AstraZeneca, Abbott, Bristol-Myers Squibb, NovoNordisk, and Roche; Rudolf de Boer has had speaker engagements with and/or received fees from and/or served on an advisory board for Abbott, AstraZeneca, Bristol Myers Squibb, NovoNordisk, Roche, and Zoll; Rudolf de Boer received travel support from Abbott and NovoNordisk. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Milton Packer has declared to have potential conflicts of interest to report: 89bio, Abbvie, Actavis, Altimmune, Alnylam, Amarin, Amgen, Ardelyx, ARMGO, AstraZeneca, Attralus, Biopeutics, Boehringer Ingelheim, Caladrius, Casana, CSL Behring, Cytokinetics, Daiichi Sankyo, Imara, Lilly, Medtronic, Moderna, Novartis, NovoNordisk, Pharmacocosmos, Regeneron, Roche, Salamandra. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

(The Center Square) — Before President Trump warned pregnant women to avoid taking Tylenol, three members of Congress dumped stock in the Fortune 500 company that makes the popular painkiller -- sell-offs that saved them from incurring sizable losses, an investigation by The Center Square found. The lawmakers sold $1,001 to $15,000 each in Kenvue Inc., a Summit, New Jersey-based consumer products company that spun off from Johnson & Johnson two years ago. The sales are notable also because most investment analysts recommended that investors hold their shares. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Op 29 september 2001 sterven zes mensen nadat ze de pijnstiller Tylenol hebben genomen. Achteraf blijkt dat cyanide in de pillen was gestopt.  Op 28 september was er al een eerste slachtoffer gevallen, een twaalfjarig meisje dat een pil nam en toen afgevoerd moest worden naar het ziekenhuis. De volgende dag werden zes mensen met dezelfde klachten naar ziekenhuizen in Chiacago gebracht. Ze zouden allemaal overlijden. Drie van hen waren familie. Als verpleegster Helen Jensen bij de slachtoffers thuis op onderzoek gaat valt het haar op dat er een nieuw potje tylenol in de kast staat. Een potje waar precies drie pillen uit zijn. Het is dankzij deze verpleegster dat er meteen groot alarm wordt geslagen en dat er niet meer slachtoffers vallen. Het blijkt dat op verschillende plekken in Chiacago is gerommeld met potjes Tylenol. De dader is nooit gepakt, maar de verdenking valt al snel op James Lewis. Die schrijft namelijk een brief aan de fabrikant van Tylenol, Johnson & Johnson, dat als ze hem één miljoen dollar geven 'het moorden op zal houden.' James Lewis wordt nooit veroordeeld voor de zes moorden, maar gaat wel twaalf jaar de bak in voor afpersing. Was hij de dader? We zullen het nooit zeker weten, want hij is inmiddels overleden.  Podcasts maken kost tijd en geld, dus wil je deze podcast steunen? Geef me vijf sterren op Spotify of een duimpje op Podimo en volg me op Instagram, TikTok, Threads of Youtube. Of koop alvast mijn nieuwe boek! Een besneeuwd kasteel, een vervloekte diamant, een gemaskerd bal, een onverklaarbare moord... Kom kerst vieren in Kasteel De Haar. Als je durft... Op 24 oktober komt Moord in Kasteel de Haar uit. In dat boek worden Joop en Nettie, het dynamische duo uit De Moord op mr. Jacques Wijsman, door barones Hélène van Zuylen uitgenodigd voor kerst op Kasteel de Haar.  Het hoogtepunt is een gemaskerd bal waar iedereen als Napoleon moet verschijnen. Tijdens het bal wordt één van de Napoleons vermoord. Wie heeft de trekker overgehaald en hebben ze eigenlijk wel de juiste Napoleon te grazen genomen? Als ze tot overmaat van ramp ingesneeuwd raken met de moordenaar moeten Joop, Nettie en Hélène zo snel mogelijk de moordenaar ontmaskeren... Ik groeide op in Haarzuilens, letterlijk om de hoek van het kasteel, heb er ook jaren als gids gewerkt. Het was altijd de droom om nog eens een boek te schrijven waarin barones Hélène allerlei avonturen zou beleven. Dit is dat boek. Moord in Kasteel de Haar is vanaf NU online overal te koop in pre-order!  Of bestel 'm direct bij mij: Liz@Doffeltje.nl

Lauren Livak Gilbert is the Executive Director of the Digital Shelf Institute (DSI), which shapes the future of digital and advances commerce through community, content, and education. In her role, she defines the strategy for creating a global industry commerce community to support brands, retailers, and future leaders in the complex digital environment. As a thought leader in digital and design, Lauren has over 10 years of experience driving impactful multichannel design content, transformative digital shelf solutions, and high-conversion web UX designs across multiple regions. Before DSI, she held numerous roles at Johnson & Johnson, where she owned the digital shelf for consumer products in North America. In this episode… The pace of change in digital commerce has forced brands to rethink their organizational structures. Traditional structures built solely for brick-and-mortar sales can no longer keep up with evolving customer expectations and constant platform updates. How can brands transform their organizations to stay relevant in the omnichannel marketplace? Seasoned digital commerce strategist Lauren Livak Gilbert urges brands to transform their overall operations instead of merely choosing where eCommerce belongs in the company. Presenting yourself to retailers as a single unified company, setting shared goals across teams, and using AI to automate tasks like forecasting and content creation are essential. Lauren also highlights the need for clean, standardized data and advises HR leaders to prepare the next generation of digital talent. These shifts position businesses to adapt quickly and thrive. In this episode of The Digital Deep Dive, Aaron Conant sits down with Lauren Livak Gilbert, Executive Director of The Digital Shelf Institute (DSI), to discuss building the reinvented omnichannel organization of the future. Lauren explains why shared goals drive higher eCommerce sales, how AI frees teams for strategic thinking, and why HR must rethink talent development.

This episode covers: Cardiology This Week: A concise summary of recent studies Strategic decisions in valvular heart disease Optimising drug therapy in chronic coronary syndromes Mythbusters: Does wearing a white coat make you smarter? Host: Susanna Price Guests: John-Paul Carpenter, Fabien Praz, Robert Storey Want to watch that episode? Go to: https://esc365.escardio.org/event/2092 Want to watch that extended interview on Optimising drug therapy in chronic coronary syndromes ? Go to: https://esc365.escardio.org/event/2092?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel, Fabien Praz and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Robert Storey has declared to have potential conflicts of interest to report: research grants and personal fees from AstraZeneca and Cytosorbents, and personal fees from Abbott, Afortiori Development/Thrombolytic Science, Boehringer Ingelheim/Lilly, Bristol Myers Squibb/Johnson & Johnson, Chiesi, Idorsia/Viatris, Novo Nordisk, PhaseBio and Tabuk. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Susanna Price Guest: Robert Storey Want to watch that extended interview? Go to: https://esc365.escardio.org/event/2092?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi.  Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Robert Storey has declared to have potential conflicts of interest to report: research grants and personal fees from AstraZeneca and Cytosorbents, and personal fees from Abbott, Afortiori Development/Thrombolytic Science, Boehringer Ingelheim/Lilly, Bristol Myers Squibb/Johnson & Johnson, Chiesi, Idorsia/Viatris, Novo Nordisk, PhaseBio and Tabuk. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Whether you've ever been a boss or have ever had a boss, you know how much those singular individuals can shape the workplace. According to studies, a good manager can increase employee engagement by as much as 70%. And, according to a survey by the American Psychological Association, a whopping 75% of employees report their boss as the worst and most stressful part of their jobs.  So, how do we know if we're being a good boss or a bad boss?  Do we just know, or should we be looking out for specific things?   Enter the incredible stories that focus on what good leaders can learn from bad bosses, featuring the author of the brand-new book, The Devil Emails at Midnight, Mita Mallick.   What to listen for: The importance of time in creating a healthier workplace culture Accountability - and how to hold others accountable, as well as check in with yourself What boss archetypes Mita has found most personally challenging  The keys to being a good boss  About our guest   Mita Mallick is a Wall Street Journal and USA Today best-selling author. She's on a mission to fix what's broken in our workplaces. She's a corporate change-maker with a track record of transforming businesses and has had an extensive career as a marketing and human resources executive. Mallick has brought her talent and expertise to companies like Unilever, Pfizer, AVON, Johnson & Johnson, Carta, and more. She's a highly sought-after speaker and business coach to start-up founders, executives, and CEOs of public companies. Her highly anticipated second book, "The Devil Emails at Midnight: What Good Leaders Can Learn from Bad Bosses," comes out September 30, 2025.    For more about the book or to purchase The Devil Emails at Midnight:  What Good Leaders Can Learn From Bad Bosses, click here:  https://www.amazon.com/dp/1394316488

About the Guest(s): Dr. Kristin Hieshetter is the host of "Functional Health Radio" and an advocate for holistic health and well-being. With extensive experience in the field of functional health, Dr. Hieshetter addresses controversial subjects in health and wellness with a focus on empathetic and fact-based conversations. Her work often involves dissecting complex medical topics and bringing light to issues that impact public health. Episode Summary: In this riveting episode of "Functional Health Radio," Dr. Kristin Hieshetter dives deep into the controversy surrounding Tylenol (acetaminophen) and its implications for pregnant women and children's health. As part two of a compelling series, Dr. Hieshetter meticulously examines studies suggesting links between acetaminophen use during pregnancy and increased risks of autism, ADHD, and other neurodevelopmental disorders in children. This episode highlights the historical, medical, and ethical concerns tied to one of the most commonly used over-the-counter medications in the world. This discussion centers around research showing acetaminophen's potential as an endocrine disruptor capable of affecting fetal brain development, with notable studies like the 2019 Journal of the American Medical Association Psychiatry article and others from UCLA and Sweden exploring this connection. Dr. Hieshetter raises awareness of these significant findings, intertwining scholarly data with her professional insights, and encourages listeners to approach this complex issue with open-mindedness and a commitment to understanding the broader implications on public health. Key Takeaways: Acetaminophen (Tylenol) use during pregnancy has been linked to increased risks of autism, ADHD, and other neurodevelopmental disorders, according to various studies. Historical issues with Johnson & Johnson's products, such as asbestos in talcum powder, highlight concerns about trust and corporate responsibility. The notion that acetaminophen disrupts hormone function during pregnancy, potentially influencing fetal brain development, is supported by multiple research findings. There is a call for further investigations and dialogue about the safety of acetaminophen, particularly concerning its use in pregnant women and children. Alternative methods for managing fever and pain, especially during pregnancy, should be considered to minimize potential risks to fetal development. Notable Quotes: "We were propagandized to believe that certain medications are safe, and now we're facing the consequences of that trust." "If this is truly what's happening, as these researchers have said, it warrants additional investigation." "The rapid increase in childhood neurodevelopmental disorders in the United States of America is unacceptable." "Maternal acetaminophen use during pregnancy is linked to a 37% rise in hyperkinetic disorders and 29% in ADHD." "We must have honest conversations about the world we've created and the legacy we want to leave behind." Resources: Journal of the American Medical Association Psychiatry (2019) - Link UCLA Study (2014) on acetaminophen and neurodevelopmental disorders. Johnson and Johnson No More Tears expose by Gardner Harris. EWG Water Safety Reports - Link Alternative Medicine Review (2009) on acetaminophen and autism. Listeners are encouraged to absorb the insights and data shared in this episode and reflect on the broader implications of acetaminophen use. For more enlightening discussions, stay tuned to "Functional Health Radio" and explore different avenues for enhancing personal and public health.

In this week's episode, we revisit our interview with Karen Long, a Managing Director at KCK (Med Tech) Group. KCK focuses on capital investment in commercial and growth-stage medical device companies. Karen has been with KCK since January 2018, when she joined as Executive-in-Residence. Karen serves as Board Director in many KCK portfolio companies as well as Independently. Prior to KCK, Karen was President and CEO of Nuelle, a women's consumer health company incubated at ExploraMed, a Silicon Valley medical device incubator. Nuelle was acquired in 2017. Karen has spent over 20 years in medical devices and diagnostics developing and marketing novel and market leading products focused on improving quality of life. She has held a series of key operating roles in consumer diagnostic companies, ChemTrak and Inverness Medical and eventually management positions at LifeScan, a Johnson & Johnson company, after the acquisition of Inverness Medical. In early 2007, Karen joined Acclarent as Worldwide Vice President of Marketing and led Acclarent's marketing efforts through rapid growth and ultimately through the acquisition by Johnson & Johnson. Karen held remained at Johnson & Johnson until joining the ExploraMed incubator in 2012. Acclarent was also an early spinout from ExploraMed. Karen began her career as a Licensed Clinical Social Worker after receiving her undergraduate and graduate degrees from San Diego State University.

How can college students step out of their comfort zone? Tim Conniff is a Keynote Speaker. He offers keynote talks that combine stand-up comedy along with a motivational message on the importance of getting out of your comfort zone, overcoming failures and avoiding negative self-talk, with clients such as Aetna, Corning, Dow Jones, Johnson & Johnson, and many more. In episode 599 of the Fraternity Foodie Podcast, we find out why Tim chose the University of Scranton, what inspired him to transition into keynote speaking and comedy, when he realized he needed to step out of his own comfort zone, what are the four zones of comfort, fear, learning, and growth, how you can reframe failure as feedback, how you can silence the inner critic and replace negative self-talk with resilience-building habits, why humor is such an effective tool for teaching personal growth, what is Tim's favorite interactive moments from a keynote, and how his message helps students find courage. Enjoy!

Ever stared at a toothpaste tube and wondered if it could take you higher? In episode 18 of Rabbit Hole, Billy Merritt and the BIT Comedy players tumble from dental conspiracies and Norwegian stop-motion cartoons to hoarding hotel soaps, prank-calling Captain Crunch, and even a pirate gang in juvie. Along the way, fluoride turns into Flo Rida, the Soggies declare war, and toothpaste becomes the most questionable substance at the Cannabis Cup. It's improv chaos at its finest: absurd connections, quick character swaps, and the kind of storytelling detours only this ensemble could conjure. From corporate “green peas” to Plato's cave, with a bit of toothpaste smoke in the air, this Rabbit Hole has it all.

A two-day conference which will examine cutting-edge technology, best practice and leadership in Maintenance, Reliability and Asset Management will be held in Kilkenny later this month. The conference will bring together over 35 exhibitors and 250 leaders from the pharmaceutical, biotech, medical device, life science, manufacturing, aerospace, industrial engineering and energy sectors. 'Reliability Ireland' takes place at the Lyrath Hotel, Kilkenny on Tuesday, September 23rd and Wednesday, September 24th. The event is designed for professionals who ensure the reliability and performance of systems, machinery, and infrastructure, as well as those shaping organisational strategy. It brings together individuals aligning asset management initiatives with broader business goals including strategy and sustainability objectives. The event will feature 18 Irish and International keynote and industry speakers, including former Ireland and Lions Rugby Captain Brian O'Driscoll; Aeronautical Engineer and STEM Advocate, Dr Norah Patten; The Mental Fitness Coach, Neil O'Brien of SkillStack; Digital Transformation and AI Specialist Kevin Rad; RCM expert Nancy Regan; with industry leaders and experts from Eli Lilly, Boston Scientific, Johnson & Johnson, Digital Manufacturing Ireland, ASHRAE and many more. The Mental Fitness Coach, Neil O'Brien of Skillstack, will be highlighting the importance of getting the basics in business right. He said: "A lot of my clients are in elite sports and I always tell them that those who achieve the best results are those who are getting the basics right and this advice can be applied to any business. Whether it's customer service, sales or leadership, a company needs to ensure that these are being done better than the competition to get ahead." Another area to be explored is AI-driven strategies in business. Digital Transformation and AI Specialist Kevin Rad said: "Companies using AI-driven strategies are already seeing a reduction of 50% in unplanned maintenance downtime and their maintenance costs have decreased by a quarter. Businesses that embrace these tools are positioning themselves ahead of the curve in efficiency, reliability, and asset performance." Bernard Yore, CEO of ESS Group, which organises the event, describes Reliability Ireland as more than a conference and exhibition. He said, "It is a foundational platform for all things reliability, maintenance and asset management. It is essential for engineers and asset management professionals looking to lead through technology, best practices and leadership." Reliability Ireland is a biennial event designed by industry, for industry and was established in 2016. Registration closes on Thursday, September 18th. For more information or to register, visit https://reliabilityireland.ie/. The key themes of Reliability Ireland 2025 are: Strategy, Leadership and Workforce Development AI, Next-Gen Technology and Digital Transformation Benchmarking, Best Practice and Data-Driven Insights Sustainability, ESG and Future-Proofing Assets Condition Monitoring and Predictive Analytics More about Irish Tech News Irish Tech News are Ireland's No. 1 Online Tech Publication and often Ireland's No.1 Tech Podcast too. You can find hundreds of fantastic previous episodes and subscribe using whatever platform you like via our Anchor.fm page here: https://anchor.fm/irish-tech-news If you'd like to be featured in an upcoming Podcast email us at Simon@IrishTechNews.ie now to discuss. Irish Tech News have a range of services available to help promote your business. Why not drop us a line at Info@IrishTechNews.ie now to find out more about how we can help you reach our audience. You can also find and follow us on Twitter, LinkedIn, Facebook, Instagram, TikTok and Snapchat.

In this episode of Investor Connect, Hall Martin speaks with Rachna Dayal, a global health biotech and venture investment expert, founder of Sugati Ventures.  Rachna shares her transition from corporate roles at Johnson & Johnson and Philips to founding and running a venture fund focused on transformative health tech startups. She talks about the major differences between working in large corporations and managing a small VC fund, emphasizing the importance of flexibility and addressing high unmet needs in healthcare through innovative solutions in medical devices and AI-enabled platforms.  Rachna highlights her investment thesis around consumer-first, purpose-led brands, particularly focusing on life-saving devices and enhancing quality of life, and discusses the crucial role of founder-market fit and diverse backgrounds in fostering innovation in the healthcare space. She also touches on current trends such as the rise of AI in healthcare and the impact of economic conditions on venture capital, offering advice for new investors and emphasizing the need for perseverance during tough times in the investment landscape.  Visit Sugati Ventures at Reach out to at   _______________________________________________________ For more episodes from Investor Connect, please visit the site at:    Check out our other podcasts here:   For Investors check out:   For Startups check out:   For eGuides check out:   For upcoming Events, check out    For Feedback please contact info@tencapital.group    Please , share, and leave a review. Music courtesy of .

What if the real secret to exceptional leadership isn't control, charisma, or even performance—but generosity? Could the “soft stuff” like listening, empathy, and vulnerability truly drive the hardest results in business? In this episode of the Delighted Customers podcast, I dig into that very question with Joe Davis, legendary former Senior Partner at Boston Consulting Group, co-founder of BCG's Washington D.C. office, and author of “The Generous Leader: Seven Ways to Give of Yourself for Everyone's Gain”. Joe shares his own journey from traditional, results-driven leadership to a generous, people-centered model—and why unlocking your team's full human potential just might be the most powerful business move you can make. We explore how the traits of generosity drive not only team happiness and loyalty, but also real bottom-line outcomes, making this conversation essential listening for leaders and aspiring leaders at every level. Why should you tune in to this episode? Joe has four decades of hands-on experience innovating in both the private and public sectors, founding major business initiatives within BCG, and working closely with Fortune 500 C-suite leaders. He distills this wisdom into practical strategies—whether you're leading a team of three or a global enterprise of 100,000. His stories from the front lines of consulting, combined with actionable steps for building trust and humanity in the workplace, will change the way you think about leadership forever. Here are three compelling questions Joe answers on the show: Why should organizations and their C-suite invest in “generous leadership” when they're held accountable for hard business outcomes, not just a healthy culture? What are the seven key traits that separate good leaders from exceptional, generous leaders—and how do they play out in real-world scenarios? How can listening, vulnerability, and small acts of recognition dramatically improve your team's performance and engagement? Listen now and subscribe to the Delighted Customers podcast on Apple Podcasts and Spotify! You'll find this episode—and every episode—on all your favorite podcast platforms. If you find value in these conversations, please leave a review and share with a friend or colleague who wants to rethink what great leadership really looks like. Meet Joe Davis Joe Davis is a veteran senior partner at Boston Consulting Group (BCG), where he spent 37 years shaping strategy, developing talent, and transforming organizations at the highest level. Joe co-founded BCG's Washington D.C. office and launched the firm's North American Public Sector business, as well as leading BCG North America. Passionate about advancing equity and inclusion, he also founded and chaired BCG's Center for Inclusion and Equity. Joe is a Harvard Business School graduate and has been at the forefront of helping organizations evolve from top-down, authoritarian structures to cultures of trust, inclusion, and generosity. His experience spans advising CEOs of major corporations to hands-on coaching with emerging leaders. He is the author of “The Generous Leader: Seven Ways to Give of Yourself for Everyone's Gain,” a groundbreaking book that reimagines the connection between caring leadership and delivering results. Joe is currently an advisor and coach to BCG's rising partners, teaching them how to inspire, motivate, and build lasting client relationships. You can reach Joe and learn more about his work via his LinkedIn profile or his website at joedavis.com. Show References and Resources “The Generous Leader: Seven Ways to Give of Yourself for Everyone's Gain” by Joe Davis Amazon Link Joe Davis on LinkedIn: https://www.linkedin.com/in/joe-davis-bcg/ Joe's personal website: https://joedavis.com Harvard Business School: https://www.hbs.edu Boston Consulting Group (BCG): https://www.bcg.com Michigan State University's Trust and Leadership Education: https://broad.msu.edu CEO Joaquin Duato, Johnson & Johnson: https://www.jnj.com/leadership/joaquin-duato Scott Kirby, CEO of United Airlines: https://www.united.com/ual/en/us/fly/company/about/leadership.html Sheila Bair, former FDIC chair: https://www.fdic.gov/about/leadership/sheila-bair/ Thank you for listening to the Delighted Customers podcast!

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WFS865. CME credit will be available until August 21, 2026.All Rise for Innovation in AML: Processing New Developments With Menin Inhibitors in Challenging AML Subtypes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WFS865. CME credit will be available until August 21, 2026.All Rise for Innovation in AML: Processing New Developments With Menin Inhibitors in Challenging AML Subtypes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WFS865. CME credit will be available until August 21, 2026.All Rise for Innovation in AML: Processing New Developments With Menin Inhibitors in Challenging AML Subtypes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WFS865. CME credit will be available until August 21, 2026.All Rise for Innovation in AML: Processing New Developments With Menin Inhibitors in Challenging AML Subtypes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WFS865. CME credit will be available until August 21, 2026.All Rise for Innovation in AML: Processing New Developments With Menin Inhibitors in Challenging AML Subtypes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WFS865. CME credit will be available until August 21, 2026.All Rise for Innovation in AML: Processing New Developments With Menin Inhibitors in Challenging AML Subtypes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WMD865. CME credit will be available until August 20, 2026.At the Nexus of Sequential Care in Myeloma: Interprofessional and Patient Perspectives on GPRC5D-Directed Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WMD865. CME credit will be available until August 20, 2026.At the Nexus of Sequential Care in Myeloma: Interprofessional and Patient Perspectives on GPRC5D-Directed Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WMD865. CME credit will be available until August 20, 2026.At the Nexus of Sequential Care in Myeloma: Interprofessional and Patient Perspectives on GPRC5D-Directed Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WMD865. CME credit will be available until August 20, 2026.At the Nexus of Sequential Care in Myeloma: Interprofessional and Patient Perspectives on GPRC5D-Directed Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WMD865. CME credit will be available until August 20, 2026.At the Nexus of Sequential Care in Myeloma: Interprofessional and Patient Perspectives on GPRC5D-Directed Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WMD865. CME credit will be available until August 20, 2026.At the Nexus of Sequential Care in Myeloma: Interprofessional and Patient Perspectives on GPRC5D-Directed Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

“Walk the talk is the most powerful way to build trust.” “Beauty grooming didn't exist—it was a new word to reflect a new purpose.”  “People didn't see themselves in the beauty industry until they started to look in the mirror.” “Recognition isn't just celebration—it's about noticing the mindset, not only the results.” Previously Hideo was Country Manager, Beauty Care Japan & Korea at Henkel; General Manager of several divisions at L'Oreal in Japan & Taiwan; Product Manager at Johnson & Johnson. He has a BA from Meiji University and an MBA form Thunderbird School Of Global Management. Hideo leads with a transformational mindset rooted in purpose, clarity, and genuine human connection. His leadership approach centers on revitalizing legacy organizations by redefining their identity and embedding a culture of innovation, joy, and self-belief. Across five successful turnaround cases in his career, Hideo discovered that real change begins not with strategy, but with a compelling purpose and vision. At Schick Japan, he introduced the idea of “beauty grooming” as a new brand identity—transforming shaving from a commodity into a value-rich, emotionally resonant experience. This pivot reimagined the business from a transactional model reliant on discounts to one driven by brand value and aspiration. To implement this shift, Hideo engaged in one-on-one conversations with all 110 employees within the first two months. This individual engagement served a dual purpose: to build trust and to carefully test and refine his ideas based on team feedback before rolling them out. Through these personal interactions, he unearthed stories—like a senior employee's joyful transformation using hair color—that became powerful internal case studies. By elevating that individual as a “beauty ambassador,” Hideo catalyzed a grassroots movement that encouraged self-care, pride, and alignment with the new company purpose. Recognizing that vision needs more than words to take hold, Hideo invested heavily in visual and cultural transformation. A dramatic office renovation served as a physical manifestation of the company's new identity. The modern, light-filled space brought the abstract idea of “joyful beauty grooming” to life and signaled serious commitment to change. This, paired with the creation of an on-site innovation studio, reinforced the values of creativity and forward momentum. Hideo believes in “walking the talk” as the cornerstone of building trust. By visibly following through on promises—whether it's office renovation, launching new products, or creating a culture of recognition—he demonstrates integrity in action. He instituted a structured recognition culture, teaching managers to appreciate not only results but also processes and mindset. He emphasizes the importance of linking every achievement back to the company's core values, reinforcing a culture that is both consistent and inspiring. His leadership style is characterized by balance—between top-down direction and bottom-up input, between Western urgency and Japanese reflection, and between innovation and cultural sensitivity. He tailors his approach depending on readiness, starting with senior leadership, cascading through middle management, and then to staff. He nurtures psychological safety by decoupling innovation from punishment, encouraging experimentation while accepting failure as part of growth. For Hideo, transformation is not a single event but a step-by-step evolution: purpose and vision, then strategy, followed by organizational alignment, early wins, recognition and celebration, and finally, values reinforcement and cultural embedding.His ability to translate abstract concepts into tangible systems and environments, while maintaining an authentic and inclusive leadership presence, has made him a standout figure in modern corporate leadership in Japan.

Wells Fargo Senior Economist Sarah House leads "The Jackson 5" analysis of key economic indicators ahead of the Fed symposium. Wedbush's Matt Bryson explains his Nvidia price target hike this week ahead of earnings. Brooke May from Evans May Wealth charts the market's next move. Plus, an exclusive look inside one of America's largest biologic drug manufacturing plants as Fujifilm's North Carolina facility prepares to produce drugs for Johnson & Johnson and Regeneron. Tom Rogers, former NBC Cable President and Versant Board senior advisor, breaks down the streaming wars as ESPN launches its new standalone app. 

In this episode of the Medical Sales Podcast, Samuel Adeyinka sits down with Gina Torres, a nurse-turned-medical device sales professional at Johnson & Johnson, to unpack what it really takes to thrive in one of the most competitive fields in healthcare: peripheral vascular and coronary sales. Gina shares her inspiring journey from working multiple nursing jobs to consolidating her career into one life-changing role in medical device sales. She reveals how she broke into the industry, why she chose Shockwave's groundbreaking intravascular lithotripsy technology, and what makes the clinical specialist role such a powerful entry point for both clinicians and driven non-clinicians. From balancing 5 a.m. case starts to late-night procedures, Gina gives a behind-the-scenes look at the unpredictable but rewarding life of a vascular rep. She also breaks down the income potential, the skills that truly separate top performers, and why grit, empathy, and the ability to “get comfortable being uncomfortable” matter more than a clinical background. Whether you're a nurse considering the leap, a bachelor's graduate wondering if you can compete, or an aspiring sales rep curious about cardiovascular devices, this conversation delivers raw insights, career strategies, and real talk about success in medical sales. Connect with Gina: LinkedIn Connect with Me: LinkedIn Love the show? Subscribe, rate, review, and share! Here's How » Want to connect with past guests and access exclusive Q&As? Join our EYS Skool Community today!

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until August 10, 2026.The Power Sequence in RRMM: Collaborative Approaches for Optimizing Sequential Treatment With Cellular and Off-the-Shelf Immunotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Johnson & Johnson, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until August 10, 2026.The Power Sequence in RRMM: Collaborative Approaches for Optimizing Sequential Treatment With Cellular and Off-the-Shelf Immunotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Johnson & Johnson, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until August 10, 2026.The Power Sequence in RRMM: Collaborative Approaches for Optimizing Sequential Treatment With Cellular and Off-the-Shelf Immunotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Johnson & Johnson, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until August 10, 2026.The Power Sequence in RRMM: Collaborative Approaches for Optimizing Sequential Treatment With Cellular and Off-the-Shelf Immunotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Johnson & Johnson, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until August 10, 2026.The Power Sequence in RRMM: Collaborative Approaches for Optimizing Sequential Treatment With Cellular and Off-the-Shelf Immunotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Johnson & Johnson, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

Host: Emer Joyce Guest: Tim Chico Want to watch that extended interview on smartwatch, heart rate and ECG? Go to: https://esc365.escardio.org/event/1811?resource=interview Want to watch that episode? Go to: https://esc365.escardio.org/event/1811   Disclaimer  ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Tim Chico has declared to have potential conflicts of interest to report: research funding from Google. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Oral anticoagulation in atrial fibrillation: answers to frequent questions Smartwatch, heart rate and ECG Milestones: Lyon Diet Heart study Host: Emer Joyce Guests: Carlos Aguiar, Tim Chico, Paulus Kirchhof Want to watch that episode? Go to: https://esc365.escardio.org/event/1811 Want to watch that extended interview on smartwatch, heart rate and ECG? Go to: https://esc365.escardio.org/event/1811?resource=interview   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Tim Chico has declared to have potential conflicts of interest to report: research funding from Google. Paulus Kirchhof has declared to have potential conflicts of interest to report: partially supported by European Union MAESTRIA (grant agreement 965286), British Heart Foundation (AA/18/2/34218), German Center for Cardiovascular Research supported by the German Ministry of Education and Research (DZHK, grant numbers DZHK FKZ 81X2800182, 81Z0710116, and 81Z0710110), German Research Foundation (Ki 509167694), Dutch Heart Foundation (DHF), the Accelerating Clinical Trials funding stream in Canada, and the Else-Kröner-Fresenius Foundation. Research support for basic, translational, and clinical research projects from German Research Foundation (DFG), European Union, British Heart Foundation, Leducq Foundation, Else-Kröner-Fresenius Foundation, Dutch Heart Foundation (DHF), the Accelerating Clinical Trials funding stream in Canada, Medical Research Council (UK), and German Center for Cardiovascular Research, from several drug and device companies active in atrial fibrillation, and has received honoraria from several such companies in the past, but not in the last five years. Listed as inventor on two issued patents held by University of Hamburg (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

In this episode, hosts Mark Longo and Dan Passarelli (Market Taker Mentoring) delve into various listener-submitted questions and trading strategies. They talk about a listener's in-depth query on a put calendar trade with Johnson & Johnson and its associated risks, and another listener's covered call strategy dubbed 'Ultra Premium Harvesting.' The hosts also answer inquiries on the use case and risks involved in trading inverse volatility products like SVXY, and discuss the optimal products and strategies for trading precious metals like gold and silver. Additionally, they address a listener's request about visiting the studio and potential local meet-ups.   01:12 Welcome to Options Bootcamp 03:10 Listener Mail Call 03:57 Ben's Epic Treatise on Put Calendars 11:39 Michael K's Ultra Premium Harvesting Strategy 17:00 Exploring Inverse Volatility Products 20:21 Trading Precious Metals 23:21 Listener Annet's Chicago Visit 25:08 Conclusion and Upcoming Episodes  

In this episode, hosts Mark Longo and Dan Passarelli (Market Taker Mentoring) delve into various listener-submitted questions and trading strategies. They talk about a listener's in-depth query on a put calendar trade with Johnson & Johnson and its associated risks, and another listener's covered call strategy dubbed 'Ultra Premium Harvesting.' The hosts also answer inquiries on the use case and risks involved in trading inverse volatility products like SVXY, and discuss the optimal products and strategies for trading precious metals like gold and silver. Additionally, they address a listener's request about visiting the studio and potential local meet-ups.   01:12 Welcome to Options Bootcamp 03:10 Listener Mail Call 03:57 Ben's Epic Treatise on Put Calendars 11:39 Michael K's Ultra Premium Harvesting Strategy 17:00 Exploring Inverse Volatility Products 20:21 Trading Precious Metals 23:21 Listener Annet's Chicago Visit 25:08 Conclusion and Upcoming Episodes  

How can biotech companies stay resilient and competitive when public sector funding becomes unpredictable? In this episode, host James Zanewicz, JD, LLM, RTTP, sits down with Adeyinka “Adey” Pierce-Watkins, MS, PMP—Director of Biodefense and Government Contracting at BDO USA—for a timely conversation on surviving and thriving in today's evolving federal funding landscape. From defense contracts to international partnerships, Adey shares practical guidance for life science leaders aiming to tap into strategic public funding opportunities. In this episode, you'll learn: How to identify and access alternative funding sources—including state, federal, and international opportunities. What biotech organizations need in place to be “government-ready” for grants, contracts, and urgent response funding. Why strategic planning, partnerships, and compliance infrastructure are essential to winning and executing federal awards. Whether you're pursuing BARDA grants, entering international consortia, or rethinking your risk exposure, this episode offers actionable insights to help biotech innovators chart a smarter path forward. Links: Connect with Adey Pierce, MS, PMP, and check out BDO USA. Connect with James Zanewicz, JD, LLM, RTTP and learn about Tulane Medicine Business Development and the School of Medicine. Learn more about the Cancer Prevention & Research Institute of Texas, TEDCO, and the California Institute for Regenerative Medicine. Learn more about Flagship Pioneering, Andreessen Horowitz, Novartis, Johnson & Johnson, and Roche. Learn more about HERA, Horizon Europe, AMED, and A*STAR. Connect with Ian McLachlan, BIO from the BAYOU producer. Check out BIO on the BAYOU and make plans to attend October 28 & 29, 2025. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD information, and to apply for credit, please visit us at PeerView.com/ZNS865. NCPD credit will be available until July 29, 2026.Leading the Next Chapter of Myeloma Care: Oncology Nurse Stewardship in the Era of Innovative Antibodies and Cellular Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from AbbVie, GSK, and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This episode covers:  Cardiology this Week: A concise summary of recent studies Atrial fibrillation in heart failure Temperature management following cardiac arrest Statistics Made Easy: Collider bias Host: Emer Joyce Guests: Carlos Aguiar, Christian Hassager, Theresa McDonagh Want to watch that episode? Go to: https://esc365.escardio.org/event/1812 Want to watch that extended interview on temperature management following cardiac arrest? Go to: https://esc365.escardio.org/event/1812?resource=interview   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Emer Joyce, Christian Hassager, Nicolle Kraenkel and Theresa McDonagh have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Emer Joyce Guest: Christian Hassager Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1812?resource=interview  Want to watch the full episode? Go to: https://esc365.escardio.org/event/1812   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Emer Joyce, Christian Hassager, Nicolle Kraenkel and Theresa McDonagh have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

In this episode of the People of Packaging podcast, host Adam Peek sits down with Michael Houston, President & CEO of Future Blue Group and Co-founder of Shower Pouch, for an insightful conversation that delves into his extensive career in packaging and his passion for innovative, sustainable solutions.Michael's Journey: From Corporate Giants to Entrepreneurial VenturesMichael shares his impressive career trajectory, starting with his time at major CPG companies like Procter & Gamble and Johnson & Johnson, where he gained invaluable experience in packaging R&D and operations. He later transitioned to companies like Beachbody, where he began to focus on helping smaller businesses navigate the complexities of product development and market entry. His experience also includes roles at Unilever, working with beauty brands like Murad, Dermalogica, and Kate Somerville, and contributing to the Honest Company's IPO. This rich background has fueled his current entrepreneurial pursuits.Introducing Shower Pouch: The On-the-Go Hygiene SolutionA significant portion of the discussion revolves around Shower Pouch, a product born from a personal problem statement. Michael recounts how his father, serving in Afghanistan, highlighted the need for a better hygiene solution than just baby wipes. Collaborating with his business partner, Omar Jimenez (a talented chemist), they developed Shower Pouch – a high-quality, durable, and highly absorbent non-woven wipe designed to clean an entire body with just one product. The conversation touches on:* The Problem: Addressing the need for convenient and effective hygiene solutions for military personnel, hospital patients, and even active individuals on the go.* The Innovation: The use of a specialized non-woven material that is highly absorbent and durable, allowing for efficient cleaning.* Sustainability Focus: Shower Pouch is designed as a durable good, emphasizing reusability and minimizing waste. The packaging even suggests washing and repurposing the wipes.* Convenience: The product can be used on its own or heated for a more comfortable experience.* Availability: Shower Pouch is available on Amazon Prime and through their website, theshowerpouch.com.Future Blue Group: Driving Sustainable Packaging for CPG BrandsMichael's consultancy, Future Blue Group, leverages his deep industry knowledge to assist CPG brands in various aspects of packaging. The discussion highlights:* Key Areas of Focus: Future Blue Group helps brands with cutting-edge technical packaging solutions, cost reduction, enhancing packaging aesthetics, improving customer experience, integrating sustainability principles, optimizing supply chain operations, and accelerating market entry.* Industry Successes: Michael notes significant success working with brands in the supplement space, where he helps optimize packaging for shelf stability and manufacturability, moving beyond generic stock options. He also finds considerable success in the personal care, masstige, and prestige categories, where he navigates complex material and formulation challenges to ensure both aesthetics and functionality.* The Importance of Data: Michael emphasizes the critical role of data in making informed packaging decisions. He advocates for a scientific, objective approach to sustainability, starting with verifiable data rather than relying on "greenwashing" or gut feelings. This is where tools like Specright.com and Trayak become invaluable.Sustainability in Packaging: A Call for ClarityMichael offers crucial advice for brands tackling sustainability:* Define Your Sustainability: He stresses the importance of clearly defining what sustainability means for your specific brand – whether it's compostability, recyclability, durability, or a combination. A clear definition allows for quantifiable goals and avoids being "all over the place."* Embrace Material Science: Understanding the materials you're working with, their manufacturing processes, and their environmental impact is key to making truly sustainable choices.* Beyond Greenwashing: Move past superficial claims and commit to science-based decisions that genuinely reduce environmental impact, particularly focusing on reducing CO2 emissions.Connect with Michael Houston:* LinkedIn: Michael Houston* Future Blue Group: Find them on LinkedIn* Shower Pouch: theshowerpouch.com* Email: michael.houston@futurebluegroup.com This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.packagingisawesome.com

This Day in Legal History: Medicare and Medicaid Signed into BeingOn July 30, 1965, President Lyndon B. Johnson signed the Social Security Amendments of 1965 into law, creating the Medicare and Medicaid programs. The signing took place at the Truman Library in Independence, Missouri, with former President Harry S. Truman—an early advocate for national health insurance—present and symbolically receiving the first Medicare card. Medicare was designed to provide hospital and medical insurance to Americans aged 65 and older, regardless of income or medical history. Medicaid, created alongside Medicare, offered healthcare assistance to low-income individuals and families.At the time, nearly half of Americans over 65 had no health insurance. The passage of Medicare was a landmark achievement of Johnson's Great Society initiative and built on decades of political struggle over healthcare reform. The legislation amended Title XVIII of the Social Security Act and was strongly opposed by many in the medical establishment and conservative politicians who labeled it as “socialized medicine.” Nevertheless, the program gained rapid popularity and provided immediate relief to millions.Administered by the federal government, Medicare initially had two parts: Part A, covering hospital insurance, and Part B, covering outpatient and physician services. It has since evolved to include prescription drug coverage (Part D) and options for private plans (Medicare Advantage). The law reshaped the American healthcare landscape and established the principle that access to healthcare for seniors was a federal responsibility.The U.S. Senate confirmed Emil Bove, a former lawyer for Donald Trump and senior Justice Department official, to a lifetime seat on the 3rd U.S. Circuit Court of Appeals in a narrow 50-49 vote. Bove faced unified Democratic opposition and criticism from over 900 former DOJ employees, who claimed he undermined the department's integrity. His nomination prompted a Democratic walkout during the Senate Judiciary Committee's vote and drew sharp condemnation from Senate Majority Leader Chuck Schumer.Despite controversy, Republicans praised Bove's background as a federal terrorism prosecutor and his legal work defending Trump in several criminal cases. His confirmation shifts the appellate court's balance back in favor of Republican appointees. Critics cited Bove's alleged directives that defied judicial authority and political interference in a corruption case against New York Mayor Eric Adams. Bove denied wrongdoing in both instances. His confirmation is part of Trump's renewed effort in his second term to reshape the judiciary, following over 230 appointments in his first term. Trump has also nominated another close adviser, Jennifer Mascott, to the same court.Trump lawyer Bove confirmed to US appeals court, overcoming Democratic opposition | ReutersBove Confirmed to Appeals Court After Whistleblowers Emerge (1)A White House crypto task force established by President Trump is set to release a highly anticipated report outlining the administration's policy goals for the digital asset sector. The report, expected Wednesday, will address tokenization, market structure legislation, and a regulatory framework for blockchain-based financial products. Created by executive order shortly after Trump took office in January, the group is led by Bo Hines and includes top officials such as Treasury Secretary Scott Bessent and SEC Chair Paul Atkins.The document is expected to support expanded use of tokenization, which converts traditional assets like stocks and real estate into blockchain-based tokens. The report may call on the SEC to create a framework enabling firms like Coinbase to offer tokenized securities, though specific language remains under wraps. It will also outline the White House's preferences for crypto legislation currently advancing in Congress, including follow-up to the recently passed stablecoin law.Trump has made pro-crypto policies a centerpiece of his administration, reversing many of the enforcement actions taken under President Biden, such as lawsuits against Coinbase and Binance. While the industry sees the report as a roadmap for mainstream integration, concerns remain about conflicts of interest, particularly given Trump's financial ties to crypto ventures and meme coins. The administration has denied any ethical violations.White House set to unveil closely watched crypto policy report | ReutersThe Trump administration has formally requested the release of grand jury transcripts related to Jeffrey Epstein and Ghislaine Maxwell, citing public interest and mounting pressure over the government's handling of the sex trafficking cases. Prosecutors filed late-night motions with U.S. District Judges Richard Berman and Paul Engelmayer, arguing that the sealed testimony should now be disclosed, though the judges had previously asked for stronger legal justification. Grand jury records are typically secret, with limited exceptions for disclosure.Trump said he directed Attorney General Pam Bondi to seek the unsealing after the Justice Department reaffirmed its conclusion that Epstein died by suicide and that there was no list of elite clients—a stance that frustrated some Trump supporters who suspect a cover-up. Epstein died in 2019 before his trial; Maxwell, convicted in 2021, is serving a 20-year sentence and has appealed to the Supreme Court to overturn her conviction.In a related effort, a Florida judge recently denied a separate request to release grand jury records from earlier state investigations into Epstein, ruling they did not meet legal exceptions. Even if the federal judges allow the current transcripts to be unsealed, the documents may not reveal new information, since much of the testimony was covered during Maxwell's trial. The transcripts also wouldn't encompass the full scope of investigative material held by the government.Deputy Attorney General Todd Blanche, a former Trump lawyer, recently met with Maxwell for two days, reportedly seeking any names or evidence she could provide about others potentially involved. Neither Blanche nor Maxwell's attorney has commented in detail on those meetings.Trump administration asks judges to release Epstein, Maxwell grand jury transcripts | ReutersA Massachusetts jury has ordered Johnson & Johnson to pay over $42 million to Paul Lovell, who developed mesothelioma after decades of using the company's talc products. Lovell and his wife sued in 2021, claiming the talc contained asbestos that he unknowingly inhaled, and accused J&J of failing to warn consumers despite knowing the risks. The jury awarded damages for pain, suffering, and medical costs.J&J denied any wrongdoing, calling the verdict “junk science” and saying its products are asbestos-free and safe, with plans to appeal the decision. The company ended U.S. sales of talc-based baby powder in 2020. This case adds to a string of multi-million-dollar verdicts against J&J in talc-related mesothelioma lawsuits, although some have been overturned on appeal.J&J is facing over 63,000 active lawsuits, and possibly up to 100,000 claims in total, most alleging ovarian cancer from talc use. The company's attempts to resolve the claims through bankruptcy have failed in court three times, including a $10 billion settlement proposal rejected in March. The Lovell case is part of ongoing litigation that continues to test J&J's legal strategy and product safety claims.Johnson & Johnson ordered to pay $42M after jury finds talc caused man's cancer | Reuters This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

Today we'll focus on a major shift in the treatment of myasthenia gravis -- as a wave of new therapies is changing how we treat this disease. Who should be considered for these new treatments? And what else is in the pipeline?   Our guest today is Dr.  Gil Wolfe, a neuromuscular neurologist at the University of Buffalo State University of New York, Jacob School of Medicine and Biomedical Sciences. Dr. Wolfe was interviewed by Dr. Ioannis Karakis, adjunct professor of neurology at Emory University School of Medicine.   References: https://www.nature.com/articles/s41598-024-79918-7   Disclosures: Dr. Wolfe discloses: Consultant for: Alexion, Argenx, BPL, Cartesian, Canopy, Grifols, Johnson & Johnson, Takeda, UCB; Speaker Bureau for: Grifols, Alexion, UCB; Grant/Research support from: ArgenX, Ra/UCB, Immunovant, Roche, Alexion, Sanofi

Carl Quintanilla and Jim Cramer explored what to make of a second day of bank earnings, led by Bank of America, Goldman Sachs and Morgan Stanley. The chip sector's record run also in the spotlight, led by Nvidia trading at all-time highs. The anchors reacted to comments made by Nvidia CEO Jensen Huang in Beijing about doing business in China. The Producer Price Index for June comes in tamer than expected, showing wholesale inflation unchanged month-on-month. Also in focus: ASML drags chip equipment stocks lower, Johnson & Johnson jumps on earnings, President Trump from trade to your 401(K), crypto legislation vote watch. Squawk on the Street Disclaimer

The title is a joke, but it's funny...and who knows, maybe it'll happen. Biggest brand deal ever? lol.Membership Specials https://swolenormousx.com/membershipsDownload The Swolenormous App https://swolenormousx.com/swolenormousappMERCH - https://papaswolio.com/Watch the full episodes here: https://rumble.com/thedailyswoleSubmit A Question⁠ For The Show: https://swolenormousx.com/apsGet On Papa Swolio's Email List: https://swolenormousx.com/emailDownload The 7 Pillars Ebook: https://swolenormousx.com/7-Pillars-EbookTry A Swolega Class From Inside Swolenormous X: https://www.swolenormousx.com/swolegaGet Your Free $10 In Bitcoin: https://www.swanbitcoin.com/papaswolio/   Questions? Email Us: Support@Swolenormous.com